Determinants of prophylactic migraine therapy in Spain;Determinantes del uso de los fármacos con indicación para la profilaxis de la migraña en España

Revista de Neurologia

Volumn 45, Issue 9, 2007, Pages 513-518

  Pascual Gomez J ^a   Caminero, A B ^b   Cano, A ^c   Heras Perez J A ^d   Leira Muino R ^e   García Ribas, Guillermo ^f  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^c HOSPITAL DE MATARÓ   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e Instituto de Salud Carlos III   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Migraine; Migraine prevention; Topiramate

Indexed keywords

AMITRIPTYLINE; FLUNARIZINE; PROPRANOLOL; TOPIRAMATE;

ADULT; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MORBIDITY; OUTPATIENT DEPARTMENT; PAIN ASSESSMENT; PROPHYLAXIS; QUESTIONNAIRE; SCALE UP; SCORING SYSTEM;

EID: 37349075117     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4509.2007472     Document Type: Article

References (38)

1. Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J. Epidemiology of headache in Europe. Eur J Neurol 2006; 13: 333-45.
2. Láinez MJA, Vioque J, Hernández-Aguado I, Titus F. Prevalence of migraine in Spain. An assessment of the questionnaire's validity by clinical interview. In Olesen J, ed. Frontiers in headache research: headache classification and epidemiology. Vol. 4. New York: Raven Press; 1994. p. 221-5.
3. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache 1994; 34: 319-28.
4. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159: 813-8.
5. Henry P, Michel P, Brochet B, Dartigues JF, Tison S, Salamon R. A nationwide survey of migraine in France: prevalence and clinical features in adults. Cephalalgia 1992; 12: 229-37.
6. Lipton RB, Stewart WF. Migraine in the United States: epidemiology and health care use. Neurology 1993; 43 (Suppl 3): S6-10.
7. Láinez JM, Castillo J, González VM, Otero M, Mateos V, Leira R, et al, Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología. Guía de recomendaciones para el tratamiento de la migraña. Rev Clin Esp 2007; 207: 190-3.
8. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-9.
9. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22: 491-512.
10. Bigal ME, Lipton RB. The preventive treatment of migraine. Neurologist 2006; 12: 204-13.
11. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population: a prevalence study. J Clin Epidemiol 1991; 44: 1147-57.
12. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Suppl 7): S1-96.
13. Stewart WF, Lipton RB, Kolodner K. Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache 2003; 43: 258-65.
14. Rasmussen BK. Epidemiology of headache. Cephalalgia 2001; 21: 774-7.
15. Edmeads J, Findlay H, Tugwell P, Pryse-Philips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20: 131-7.
16. Hagen K, Zwart JA, Vatten L, Stovner LJ, Bovim G. Prevalence of migraine and non-migrainous headache -head HUNT, a large population-based study. Cephalalgia 2000; 20: 900-6.
17. O'Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol 1994; 23: 1020-6.
18. Jiménez-Caballero PE. Análisis de las cefaleas atendidas en las guardias de Neurología. Rev Neurol 2005; 40: 648-51.
19. García-Escrivà A, Asensio-Asensio M, López- Hernández N, González-Aznar OJ, Oliver-Navarrete C, Álvarez-Saúco M, et al. Actividad asistencial en una consulta específica de cefalea. Rev Neurol 2004; 39: 401-5.
20. Leira R, Láinez JM, Pascual J, Díez-Tejedor E, Morales F, Titus F, et al. Estudio español de calidad de vida en migraña (I). Perfil del paciente con migraña que acude a consultas de neurología. Neurologia 1998; 13: 287-91.
21. Kanieck RG. Migraine and tension-type headache: an assessment of challenges in diagnosis. Neurology 2002; 58: 15-20.
22. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort. The GEM study. Neurology 1999; 53: 537-42.
23. Gracia-Naya M, Latorre-Jiménez A. Valoración de la efectividad del topiramato en el tratamiento preventivo de la migraña. Estudio observacional de una serie consecutiva de pacientes. Neurologia 2005; 20: 225-31.
24. Fernández-Concepción O, Canuet-Delis L. Discapacidad y calidad de vida en pacientes con migraña: factores determinantes. Rev Neurol 2003; 36: 1105-12.
25. Brown JS, Papadopoulos G, Neumann PJ, Friedman M, Miller JD, Menzin J. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005; 45: 1012-22.
26. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 1994; 44 (Suppl 4): S24-39.
27. Rapoport AM, Bigal ME. Migraine preventive therapy: current and emerging treatment options. Neurol Sci 2005; 26 (Suppl 2): S111-20.
28. Pascual J, Leira R, Lainez JM, Alberca R, Titus F, Morales F, et al. Estudio español de calidad de vida en la migraña (II). Patrón de consumo de fármacos y eficacia subjetiva. Neurologia 1999; 14: 204-9.
29. Medrano V, Sempere AP, Morera-Guitart J, Fernández-Izquierdo S, Espinosa-Martínez J. El tratamiento preventivo con topiramato mejora la calidad de vida de los pacientes con migraña. Rev Neurol 2006; 43: 259-63.
30. Brandes JL, Kudrow DB, Rothrock JF, Rupnow MF, Fairclough DL, Greenberg SJ. Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc 2006; 81: 1311-9.
31. Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin 2006; 22: 1021-9.
32. Shapiro RE. Topiramate for migraine prevention: a randomized controlled trial. J Pediatr 2004; 145: 419-20.
33. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-5.
34. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965-73.
35. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001; 41: 968-75.
36. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 754-62.
37. Morey SS. Guidelines on migraine: part 5. Recommendations for specific prophylactic drugs. Am Fam Physician 2000; 62: 2535-9.
38. Grupo de Estudio de Cefalea de la Sociedad Española de Neurología. Actitud diagnóstica y terapéutica en la cefalea: recomendaciones 2006. Madrid: Ergón; 2006.